Cautious View Warranted on Sonic's German, U.S. Operations -- Market Talk

Dow Jones

Feb 11

0111 GMT - UBS cuts its price target on Sonic Healthcare by 26% to A$21.80/share when restarting coverage of the stock, citing a more cautious view of the outlook for the company's German and U.S. operations. That caution reflects the risk of funding cuts in Germany and increased competition in the U.S. In Germany, potential reforms to private patient funding appear well progressed, analyst David Low says. Those revisions are likely to come into effect during FY 2027. "The structure of the German system suggests diagnostic providers will be disadvantaged," UBS says. "We have allowed for some margin pressure from FY27, although limited detail makes the ultimate impact hard to quantify." UBS has a neutral call on Sonic, which is up 1.7% at A$22.19. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

February 10, 2026 20:11 ET (01:11 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610488603"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610488603\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610488603?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 09:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610488603","market":"hk","top_or_hot":-1,"title":"Cautious View Warranted on Sonic's German, U.S. Operations -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0111 GMT - UBS cuts its price target on <a href=\"https://laohu8.com/S/SKHCF\">Sonic Healthcare</a> by 26% to A$21.80/share when restarting coverage of the stock, citing a more cautious view of the outlook for the company's German and U.S. operations. That caution reflects the risk of funding cuts in Germany and increased competition in the U.S. In Germany, potential reforms to private patient funding appear well progressed, analyst David Low says. Those revisions are likely to come into effect during FY 2027. \"The structure of the German system suggests diagnostic providers will be disadvantaged,\" UBS says. \"We have allowed for some margin pressure from FY27, although limited detail makes the ultimate impact hard to quantify.\" UBS has a neutral call on Sonic, which is up 1.7% at A$22.19. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 20:11 ET (01:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cautious View Warranted on Sonic's German, U.S. Operations -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCautious View Warranted on Sonic's German, U.S. Operations -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-11 09:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0111 GMT - UBS cuts its price target on <a href=\"https://laohu8.com/S/SKHCF\">Sonic Healthcare</a> by 26% to A$21.80/share when restarting coverage of the stock, citing a more cautious view of the outlook for the company's German and U.S. operations. That caution reflects the risk of funding cuts in Germany and increased competition in the U.S. In Germany, potential reforms to private patient funding appear well progressed, analyst David Low says. Those revisions are likely to come into effect during FY 2027. \"The structure of the German system suggests diagnostic providers will be disadvantaged,\" UBS says. \"We have allowed for some margin pressure from FY27, although limited detail makes the ultimate impact hard to quantify.\" UBS has a neutral call on Sonic, which is up 1.7% at A$22.19. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 10, 2026 20:11 ET (01:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SHL.AU","symbol_name":"SONIC HEALTHCARE LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2610488603","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610488603","pubTimestamp":1770772260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0111 GMT - UBS cuts its price target on Sonic Healthcare by 26% to A$21.80/share when restarting coverage of the stock, citing a more cautious view of the outlook for the company's German and U.S. operations. That caution reflects the risk of funding cuts in Germany and increased competition in the U.S. In Germany, potential reforms to private patient funding appear well progressed, analyst David Low says. Those revisions are likely to come into effect during FY 2027. \"The structure of the German system suggests diagnostic providers will be disadvantaged,\" UBS says. \"We have allowed for some margin pressure from FY27, although limited detail makes the ultimate impact hard to quantify.\" UBS has a neutral call on Sonic, which is up 1.7% at A$22.19. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SHL.AU":"SONIC HEALTHCARE LTD","BK7124":"保健护理服务"},"translate_title":"对Sonic的德国和美国业务持谨慎态度——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SHL.AU":0.9},"content_text":"0111 GMT - UBS cuts its price target on Sonic Healthcare by 26% to A$21.80/share when restarting coverage of the stock, citing a more cautious view of the outlook for the company's German and U.S. operations. That caution reflects the risk of funding cuts in Germany and increased competition in the U.S. In Germany, potential reforms to private patient funding appear well progressed, analyst David Low says. Those revisions are likely to come into effect during FY 2027. \"The structure of the German system suggests diagnostic providers will be disadvantaged,\" UBS says. \"We have allowed for some margin pressure from FY27, although limited detail makes the ultimate impact hard to quantify.\" UBS has a neutral call on Sonic, which is up 1.7% at A$22.19. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 20:11 ET (01:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}